CN1698688A - Compound defervesce foam for children - Google Patents

Compound defervesce foam for children Download PDF

Info

Publication number
CN1698688A
CN1698688A CNA2004100405907A CN200410040590A CN1698688A CN 1698688 A CN1698688 A CN 1698688A CN A2004100405907 A CNA2004100405907 A CN A2004100405907A CN 200410040590 A CN200410040590 A CN 200410040590A CN 1698688 A CN1698688 A CN 1698688A
Authority
CN
China
Prior art keywords
parts
foam
ethanol
propylene glycol
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA2004100405907A
Other languages
Chinese (zh)
Other versions
CN1292761C (en
Inventor
柴立
李霞
周飞
余德勤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HONGYU PHARMACEUTICAL CO Ltd GUIZHOU PROV
Original Assignee
HONGYU PHARMACEUTICAL CO Ltd GUIZHOU PROV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HONGYU PHARMACEUTICAL CO Ltd GUIZHOU PROV filed Critical HONGYU PHARMACEUTICAL CO Ltd GUIZHOU PROV
Priority to CNB2004100405907A priority Critical patent/CN1292761C/en
Publication of CN1698688A publication Critical patent/CN1698688A/en
Application granted granted Critical
Publication of CN1292761C publication Critical patent/CN1292761C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention discloses a compound defervesce foam for children, which is prepared from the raw materials of acetaminopher, artificial ox gallstone, isatic root powder, propylene glycol, polyvidon K3O, stearic acid, lanoline and ethanol through the following steps, mixing homogeneously, stirring homogeneously, split charging, pushing in casting agent, and loading into bottles.

Description

The compound infantile foam of bringing down a fever
Technical field
The present invention relates to a kind of pharmaceutical preparation, particularly a kind of pharmaceutical foam agent for the treatment of pediatric disease.
Background technology
Paracetamol compound suppository is the conventional medicine of infantile fever such as treatment fever of children and upper respiratory tract infection.This medicine is the Chinese medicine and western medicine compound preparation, through clinical verification for many years, and its determined curative effect, without any side effects.But suppository exists one to dissolve dispose procedure at internal rectum, and owing to be local contact, and is little with the mucous membrane of rectum contact area, may the induce drug inflammation; The local concentration height can cause infiltration rate slow, and the performance drug effect is slow, uses inconvenience.
Summary of the invention
The objective of the invention is to, a kind of compound infantile foam of bringing down a fever is provided.This foam dissolves that to discharge medicine fast, and big with the mucous membrane of rectum contact area, infiltration rate is fast, and the performance drug effect is fast and lasting, easy to use, better efficacy.
Technical scheme of the present invention is, the compound infantile foam of bringing down a fever is characterized in that it is to be made by the following weight proportion raw material:
2~3 parts of 60~65 parts of artificial Calculus Boviss of acetaminophen
70~80 parts of 20~22 parts of propylene glycol of Rhizoma Et Radix Baphicacanthis Cusiae extractum powder
8~20 parts of 30 1~5 parts of stearic acid of 30 POVIDONE K 30 BP/USP
200~250 parts of 1~5 part of ethanol of lanoline
90~120 parts of purified water
Preparation method is, gets acetaminophen, Rhizoma Et Radix Baphicacanthis Cusiae extractum powder and 30 POVIDONE K 30 BP/USP 30, adds 2/3rds amount propylene glycol, ethanol and purified water mix homogeneously in 75 ℃ water-bath; Add emulsifying agents such as stearic acid, lanoline again after the propylene glycol mixing dissolving of artificial Calculus Bovis elder generation and remainder and in 77 ℃ water-bath, fully be dissolved into mixed solution, mix homogeneously; The solution of two parts mix homogeneously is mixed in 60 ℃ of water-baths, stir, packing is pressed into propellant, and bottling gets product.
Above-mentioned compound infantile is brought down a fever in the foam, and described materials of weight proportions is reasonable to be:
2 parts of 62.5 parts of artificial Calculus Boviss of acetaminophen
50 parts of 20.8 parts of propylene glycol of Rhizoma Et Radix Baphicacanthis Cusiae extractum powder
12.5 parts of 30 1.7 parts of stearic acid of 30 POVIDONE K 30 BP/USP
225 parts of 1 part of ethanol of lanoline
94.2 parts of purified water
Requirement according to the foam dosage form: should be evenly not stratified, in the lacuna holdup time long, and the efficacy of a drug is comparatively lasting, the ejection total amount should be not less than 85%, in order to reach above-mentioned requirements, we adopt o/w type Emulsion and thickening agent and freon as propellant.By analyzing and screening,, the adjuvant and the consumption that are suitable for have been determined through testing repeatedly, contrast, summing up with the use and the consumption thereof of orthogonal experiment to adjuvant.
The experiment that the present invention did
The quasi-factor design method in the orthogonal test is adopted in this experiment, and according to documents and materials and trial test result, we select 30 POVIDONE K 30 BP/USP 30, propylene glycol, stearic acid, lanoline, freon five factors for use, considers that simultaneously four levels adopt L 16(4 5) arrange orthogonal test to the bring down a fever influence of foam quality of compound infantile, found out the best ratio of each factor.
1, method and result
1.1 preparation technology: with acetaminophen, Rhizoma Et Radix Baphicacanthis Cusiae extractum powder and 30 POVIDONE K 30 BP/USP 30, ethanol, 2/3rds propylene glycol, the purified water mix homogeneously of measuring in 75 ℃ water-bath of recipe quantity; Add emulsifying agents such as stearic acid, lanoline again after the propylene glycol mixing dissolving of artificial Calculus Bovis elder generation and remainder and in 77 ℃ water-bath, fully be dissolved into mixed solution, mix homogeneously; The solution of two parts mix homogeneously is mixed in 60 ℃ of water-baths, stir, packing is pressed into propellant, and bottling gets product.
1.2 preparation process condition preferably sees Table 1 and table 2, table 3.After allotting liquid medicine filling, spray volume of foam (cm 3) and foam duration (min) and the ejection total amount (%) carry out comprehensive grading.Wherein hold speed time (min) medicinal liquid is sprayed into graduated cylinder, put 37 ℃ of observing in water-soluble.Calculate according to tripartite mask body situation.
Table 1 investigation factor and level
Level Factor
A (stearic acid dosage %) B (propylene glycol consumption %) C (polyvidone consumption %) D (lanoline consumption %) E (freon consumption %)
??1 ?1.8 ?0 ?0.34 ?0.15 ?25
??2 ?2.5 ?10 ?0.29 ?0.3 ?30
??3 ?3.6 ?15 ?0.17 ?0.1 ?40
??4 ?2.0 ?20 ?0.46 ?0.2 ?35
Table 2 Orthogonal Experiment and Design table
Table 3 analysis of variance table
Soruces of variation Sum of deviation square Degree of freedom Variance The F value
??A ??2082.19 ??3 ??694.06 ??2.62
??B ??2232.69 ??3 ??744.23 ??2.80
??C ??1630.69 ??3 ??543.56 ??2.05
??D ??716.19 ??3 ??265.40
??E ??3498.69 ??3 ??1166.23 ??4.39
Interpretation of result his-and-hers watches 2, table 3 columns carry out intuitive analysis and variance analysis, and the result shows: optimised process is A 2B 2C 1D 4E 3, promptly the propylene glycol consumption is 10%, and the polyvidone consumption is 0.34%, and stearic acid dosage is 2.5%, and the lanoline consumption is 0.2%, the freon consumption is that the resultant effect of 40% o'clock product is best.R E>R B>R A>R C>R D,E>B>A>C>D。
Experiment adopts the comprehensive grading method that bring down a fever foam duration, ejection total amount, the ejection volume of foam of compound infantile carried out comprehensive grading, selects optimised process, experimentizes by optimised process, and made finished product is through observing and check.Stability better, meet quality standard.
Foam aerosol of the present invention has the advantages that activity is high and the holdup time is long, and its usefulness performance is faster than general peroral dosage form, suppository.The present invention and suppository show in pharmacology, toxicity contrast test: the present invention uses more convenient, and dosage is easy to grasp, and is applicable to that more children's uses.Zoopery proves, to noninfectious fever---inject the foreign preteins fever model, and infective fever---inject typhoid fever, paratyphoid fever fever model, significant refrigeration function is all arranged, after medication half an hour, each administration group body temperature all obviously descends, and compares with adstante febre body temperature, have significant difference, P<below 0.05.Cooling effect can be kept 3 hours.Cooling effect shows certain dose-effect dependency.Analgesic experiment is the result show, the present invention has remarkable analgesic activity, can obviously improve the threshold of pain of mice, compare with suppository, have the difference of highly significant, in the time of 20 minutes 100mg/kg group P<0.05,200mg/kg organizes P<0.02, and 400mg/kg organizes P<0.001, has good dose-effect relationship.The experimental result of writhing method is similar to hot plate method, and the body number of times of turning round of foam group obviously is less than the suppository group, and this explanation foam all has better analgesic activity to the pain due to physical property stimulation and the chemical irritation.After experiment showed, that this pharmaceutically dosage form of the present invention changes, do not influence its analgesic, analgesic activity.This dosage form toxic and side effects is little, is easy to tolerance.
The present invention shows that through clinical trial its effective percentage is better than suppository up to 94.5%.Antipyretic-antalgic there is good effect.
Compare with original suppository, the present invention is a kind of new pharmaceutical dosage form.The holdup time of the present invention in lacuna is long, and its usefulness performance is faster than peroral dosage form, suppository.It is more convenient that the present invention has use, and dosage is easy to grasp, and better efficacy more is applicable to the characteristics that children's uses.
The specific embodiment:
Embodiment 1, gets raw material by following weight proportion:
Acetaminophen 2250g artificial Calculus Bovis 75g
Rhizoma Et Radix Baphicacanthis Cusiae extractum powder 750g propylene glycol 1800g
30 POVIDONE K 30 BP/USP 30 61.2g stearic acid 450g
Lanoline 36g ethanol (95%) 8100g
Purified water 3391g
Preparation method is, gets acetyl aminophenol, Rhizoma Et Radix Baphicacanthis Cusiae extractum powder and 30 POVIDONE K 30 BP/USP 30 and mixes, and adds 1200g propylene glycol, ethanol (95%), purified water mix homogeneously in 75 ℃ water-bath again; Add emulsifying agents such as stearic acid, lanoline again after the propylene glycol mixing dissolving of artificial Calculus Bovis elder generation and remainder and in 77 ℃ water-bath, fully be dissolved into mixed solution, mix homogeneously; The solution of two parts mix homogeneously is mixed in 60 ℃ of water-baths, stir, packing is pressed into propellant, dresses up 1000 bottles, the compound infantile that the gets product foam of bringing down a fever.This product is a rectal application.Using method is: 1~2 time on the one.Use preceding first jolting even, propeller is placed on the valve, the promptly full propeller of pressing valve, foam inserts propeller the about 3cm of anus more gently, and foam is injected anus.Inject two envelope foams for using once amount (children's was 1 time on the one in to three years old, three to six years old 2 times on the one).

Claims (3)

1, the compound infantile foam of bringing down a fever is characterized in that it is to be made by the following weight proportion raw material:
2~3 parts of 60~65 parts of artificial Calculus Boviss of acetaminophen
40~55 parts of 20~22 parts of propylene glycol of Rhizoma Et Radix Baphicacanthis Cusiae extractum powder
8~20 parts of 30 1~5 parts of stearic acid of 30 POVIDONE K 30 BP/USP
200~250 parts of 1~5 part of ethanol of lanoline
90~120 parts of purified water
Preparation method is, gets acetaminophen, Rhizoma Et Radix Baphicacanthis Cusiae extractum powder and 30 POVIDONE K 30 BP/USP 30, adds 2/3rds amount propylene glycol, ethanol and purified water mix homogeneously in 75 ℃ water-bath; Add emulsifying agents such as stearic acid, lanoline again after the propylene glycol mixing dissolving of artificial Calculus Bovis elder generation and remainder and in 77 ℃ water-bath, fully be dissolved into mixed solution, mix homogeneously; The solution of two parts mix homogeneously is mixed in 60 ℃ of water-baths, stir, packing is pressed into propellant, and bottling gets product.
2, the compound infantile according to claim 1 foam of bringing down a fever is characterized in that described materials of weight proportions is:
2 parts of 62.5 parts of artificial Calculus Boviss of acetaminophen
50 parts of 20.8 parts of propylene glycol of Rhizoma Et Radix Baphicacanthis Cusiae extractum powder
12.5 parts of 30 1.7 parts of stearic acid of 30 POVIDONE K 30 BP/USP
225 parts of 1 part of ethanol of lanoline
94.2 parts of purified water
3, the compound infantile according to claim 1 and 2 foam of bringing down a fever is characterized in that described ethanol is the ethanol of concentration 95%.
CNB2004100405907A 2004-08-30 2004-08-30 Compound defervesce foam for children Active CN1292761C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2004100405907A CN1292761C (en) 2004-08-30 2004-08-30 Compound defervesce foam for children

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2004100405907A CN1292761C (en) 2004-08-30 2004-08-30 Compound defervesce foam for children

Publications (2)

Publication Number Publication Date
CN1698688A true CN1698688A (en) 2005-11-23
CN1292761C CN1292761C (en) 2007-01-03

Family

ID=35475039

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004100405907A Active CN1292761C (en) 2004-08-30 2004-08-30 Compound defervesce foam for children

Country Status (1)

Country Link
CN (1) CN1292761C (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104147063A (en) * 2014-08-07 2014-11-19 江西九华药业有限公司 Compound pediatric antipyretic suppository and preparation method thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104147063A (en) * 2014-08-07 2014-11-19 江西九华药业有限公司 Compound pediatric antipyretic suppository and preparation method thereof

Also Published As

Publication number Publication date
CN1292761C (en) 2007-01-03

Similar Documents

Publication Publication Date Title
Laughlin et al. Cytokine involvement in dynorphin-induced allodynia
ISHIDA et al. Mucosal dosage form of lidocaine for toothache using hydroxypropyl cellulose and carbopol
MXPA04006198A (en) METHOD OF SYSTEMICALLY DELIVERING SSRIs.
CN1515286A (en) Chinese medicinal herb extractive
CN1292761C (en) Compound defervesce foam for children
CN101147735A (en) Pharmaceutical composition for injection and its medicine box
CN1686294A (en) Medicinal composition for treating coronary heart disease stenocardia
CN112439070A (en) Sidapamide pharmaceutical composition and application thereof
CN1943707A (en) A Chinese traditional medicinal composition for anti-aging and its preparation method
CN1179726C (en) Application of naringin in preparing medicine for supporting treatment of SARS
CN1217669C (en) Naringin used in preparing medicine for curing acute and chronic bronchitis
CN1194665C (en) Preparing method for superfine Chinese medicine jellies
CN1259905C (en) Use of Rhizoma-Curcumae-Longae element in preparing medicine for treating lung disease
CN1846775A (en) New medicinal use of Chinese medicine nutmeg and its extract
CN1415303A (en) Red sage root and Tienchi sustained release medication, its preparation method and medicinal application in vascular dementia
CN105497898A (en) Application of MAPK signal pathway inhibitor to preparation of drugs for treating cystic echinococcosis
CN1107501C (en) Albendazole emulsion
CN108096241B (en) Medical application of ginkgolide composition
CN111662302A (en) Compounds and compositions thereof for the treatment of polycystic ovarian syndrome
CN110840875A (en) Application of borneol cinnamate in preparing medicine for treating hyperplasia of mammary glands
CN100339133C (en) Composition of nanometer SOD and astragalus root or its extract and its preparation method
CN112656794B (en) Application of pyrroloquinoline quinone or salt thereof in preparation of medicines for preventing and treating prostatic hyperplasia and pharmaceutical composition
CN114159435B (en) Application of Fuziling in preparing medicine for treating arthritis
CN1813836A (en) Medicinal composition for treating cardio-cerebrovascular disease
Kaboutari et al. Anti-inflammatory evaluation of the novel slow-release curcumin-loaded selenium nanoparticles in the experimental peritonitis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant